United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

EMA's move paves way for inoculations to begin across Europe within next few days

Pfizer/BioNTech Covid vaccine approved by European regulator

Pfizer Inc. (NYSE: PFE)-BioNTech SE's – ADR (NASDAQ: BNTX) coronavirus vaccine candidate – BNT162b2 – is inching closer to getting conditional approval in European Union, after similar approvals in the U.S., U.K., Bahrain Saudi Arabia, Canada, Mexico and Switzerland. What Happened: Following a rigorous evaluation of BNT162b2, which is to go by the trade name Comirnaty in Europe, the European Medicines Agency's Committee For Medicinal Products For Human Use concluded by consensus that sufficiently robust data on the safety and efficacy of the vaccine are now available to recommend a formal conditional marketing authorization.

EMA Committee Recommends Conditional Approval Of Pfizer-BioNTech Vaccine In Europe

Alexandria Real Estate Equities

Cerner

Illumina

Intuitive Surgical

Teladoc

Zoetis

True, there are political risks in the industry. But there are also lots of growth opportunities for investors in healthcare stocks.

7 Healthcare Stocks to Buy With the Sector Under Scrutiny

The European Union has authorized its first vaccine against Covid-19, joining the U.S. and the U.K. in allowing the shots developed by Pfizer and BioNTech.

European Union Approves Pfizer-BioNTech Covid Vaccine

The European Union has so far managed to secure 2 billion doses of various Covid-19 vaccines.

EU Drug Regulator Approves Pfizer-BioNTech Covid-19 Vaccine For Emergency Use

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

European Regulators Clear Pfizer's Covid-19 Vaccine

Europe's medicines regulator on Monday approved the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer and its German partner BioNTech, putting Europe on course to start inoculations within a week.

Regulator clears way for use of Pfizer COVID-19 vaccine in Europe

The European Commission should give its decision by Monday evening on the COVID-19 vaccine developed by Pfizer and BioNTech, which should pave the wave for vaccinations to begin across the 27 EU countries this year.

EU to decide on Pfizer/BioNTech COVID-19 vaccine by evening, EU chief

The European drug regulator said on Monday the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer and its German partner BioNTech on pregnant women should be done on a case by case basis.

EU drug regulator: Pfizer-BioNTech vaccine should be on case by case for pregnant women

The European Union drug regulator recommended the EU authorize the Pfizer and BioNtech COVID-19 vaccine on Monday. Experts on the European Medicines Agency's human medicines committee concluded the Pfizer vaccine was safe and effective for people 16-years-old and older using available data. The decision will lead the way for a EU-wide authorization of the vaccine.

European Medicines Agency just recommended the Pfizer and BioNtech COVID-19 vaccine for use in EU

The European Medicines Agency said it had recommended granting conditional marketing authorization for the vaccine in people aged 16 and over.

European Medicines Agency authorizes Pfizer vaccine for use in the EU

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion to recommend the conditional marketing authorization (CMA) of the Pfizer-BioNTech COVID-19 Vaccine (also known as BNT162b2), for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. The purpose of a

Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine

Home Depot

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Thanks to their safe dividends, you can rely on these mega-cap stocks to not only survive tough times, but pay you while you wait. The post 3 Mega-Cap Stocks for Safe Dividends appeared first on InvestorPlace.

3 Mega-Cap Stocks for Safe Dividends

Moderna

Stocks Set to Confront the Virus in 2021 (NASDAQ: MRNA) (OTC: HALB) (NYSE: PFE)

A week into the COVID-19 mass vaccination efforts, the U.S. Centers For Disease Control and Prevention reports that — of the 2,838,225 doses distributed around the country — over 556,208 doses had been administered as of Sunday. What Happened: The U.S. Food and Drug Administration has approved two vaccine candidates so far.

CDC Says Over 556,208 Pfizer/BioNTech COVID-19 Shots Administered In Week 1 Of Inoculation Drive

Fastly

Airbnb

These companies have already delivered handsome profits to their shareholders in 2020, but their growth prospects mean they remain solid buys.

3 Top Breakout Stocks to Watch in 2021

You're not the only one wondering if this dividend-paying pharma stock deserves a place in a portfolio.

4 Reasons You Should Buy Pfizer Stock Right Now

And it could be a long time before we know the answer.

$40 Billion Per Year for COVID Vaccine Makers Hinges on This 1 Unanswered Question

Manufacturing is a black box for investors.

Here's What Investors Need to Know About Pfizer and BioNTech's Vaccine Launch

It could be the beginning of the end for the pandemic.

Here's Why Pfizer's Vaccine Is So Important

One healthcare company is confident about its future while the other tries to recapture its former glory.

Better Coronavirus Stock: Pfizer vs. BioNTech

The FDA gave this pharmaceutical company's COVID-19 vaccine the green light for emergency use, but does that make it a sound investment?

Is Pfizer Stock a Good Bet on Coronavirus Vaccines?

Much like the effort to put a man on the moon, the Covid-19 vaccine is historic. But there are other drivers for Pfizer stock as well.

Pfizer Stock and the Modern-Day Apollo Program

Pfizer said Thursday that millions of COVID-19 vaccines are sitting in storage because the US government hasn't given it directions on where to send them yet.  The statement was released a day after Health and Human Services Secretary Alex Azar suggested at a press conference that the drug company was having "manufacturing challenges," The Hill reported. 

News for Pfizer Stock (PFE)